hemophilia

View All

emerging-rna-interference-drugs
RNA Interference: New Class of Drugs In The Fight Against Disease

RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...

Find More

Pharma News for AbbVie and Sobi
Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200

Novo Nordisk Reports Phase III Results of Concizumab Drug for Hemophilia A or B Novo Nordisk has announced Phase III results for their concizumab drug for hemophilia A or B, demonstrating efficacy in preventing bleeding events and paving the way for regulatory filings later this year. Concizumab, an anti-tissue ...

Find More

Pharma News for Ipsen, BioMarin and AbbVie
Ipsen to Buy Epizyme; BioMarin’s Gene Therapy for Hemophilia; AbbVie’s Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen

Ipsen to Buy Biopharmaceutical Company Epizyme for USD 247 Million The restructuring of French manufacturer Ipsen has progressed with a takeover agreement for US competitor Epizyme and its cancer drug Tazverik in a deal for slightly less than USD 250 million. Ipsen is proposing USD 1.45 per share for Epizyme, va...

Find More

Introducing a New Era of Hemophilia Management Tools
Role of Mobile Technology in Hemophilia Management

The universality of mobile technology has proven to be extremely beneficial, specifically in recent years. The potential of improving medical care delivery, and the potential for instantaneous and two-way transfer of information has turned out to be a revolutionary step. The following article indicates the importan...

Find More

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Patients with more severe forms of the disease can experience s...

Find More

bleeding-disorders-therapeutics-market-size-share-trends-growth-forecast
Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?

Bleeding disorders, also known as coagulopathy, are a group of conditions in which the blood cannot clot properly due to the missing or defective protein. Bleeding Disorder can affect a person irrespective of his genders, ages and race and the person is likely to bleed more than the average person. A minor cut or s...

Find More

hemophilia-b-market
Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?

An X-linked recessive disorder, Hemophilia occurs predominantly in males with females being the carriers. Patients diagnosed with Hemophilia usually lack one of the two proteins essential for the blood coagulation cascade namely factor VIII (FVIII) and factor IX (FIX). On the basis of the different blood coagulatio...

Find More

Hemophilia Market | A rare bleeding disorder | A royal disease
A Royal Disease: Hemophilia

A Royal Disease: Hemophilia  During the 19th-century British monarch's son Leopold, Duke of Albany slipped and died of blood loss. Not only once, but Queen Victoria’s grandsons died at a comparatively younger age. Thus, it was thought that male descendants of the royal family are cursed. Hence, the assumed ...

Find More

Hemophilia: A Lifelong Genetic Disorder

Hemophilia is a rare congenital disorder which impairs the ability of the blood to clot properly. This disorder is characterized by the bleeding into the joints which leads to swelling and pain or tightness in the joints. It also causes bleeding into the skin which results in building up of blood in hematoma. Studie...

Find More

Hemophilia A- Market Scenario

Hemophilia is the most common inherited bleeding disorder which leads to spontaneous bleeding as the blood does not clot properly. Hemophilia, characterized by the spontaneous bleeding and swollen joints due to bleeding into the joints, is of several different types- such as Hemophilia A, Hemophilia B, and...

Find More